

**Characterisation of the Transcriptome and
Proteome of *Salmonella enterica* subspecies
enterica serovar Typhi.**

**Thesis submitted to the University of Cambridge for the degree of Doctor of
Philosophy**

2nd January 2009

**Timothy Trevor Perkins
Jesus College**

Declaration

I hereby declare that this thesis consists of work derived entirely of my own work. Due to the nature of this work, and interdisciplinary nature of biological sciences, it was not possible and impractical to perform all of these techniques, however, it was possible to design all experiments associated with this thesis. Work that was done by other persons is clearly stated in the Materials and Methods section.

This thesis is no longer than 300 pages as required by the Department of Biological Sciences.

Abstract

Salmonella enterica subspecies *enterica* serovar Typhi (*S. Typhi*) is the cause of human typhoid. A combination of approaches were utilised to analyse the transcriptome and proteome of this human-restricted and highly clonal pathogen.

A novel method for strand-specific RNA-seq was developed, facilitating a whole genome analysis of the *S. Typhi* Ty2 BRD948 transcriptome. These data were validated using novel analyses methods and compared to RNA derived from an *ompR* mutant derivative. The data was used to reinterpret a previous annotation of the *S. Typhi* Ty2 genome. Mass Spectrometry sequenced peptides were mapped back to the genome to further enhance the quality of the annotated data of the *S. Typhi* genome.

DNA microarray analysis was used to quantify differences in gene expression between wild type and a *S. Typhi* Ty2 *ompR* mutant and identify genes, which were significantly differentially expressed in both transcriptome sequencing and microarray experiments. A subset of genes that were OmpR-regulated, hypothetical and absent from *E. coli* were identified to evaluate their virulence potential using *S. Typhimurium* mutant derivatives and *in vitro* assays. Protein homology searches were used to explore the potential function of several novel OmpR-regulated proteins. Finally, applying new DNA sequencing technology allowed development of a chIP-seq protocol to identify OmpR-binding sites.

“The last thing I'll say to the people that don't believe in cycling – the cynics, the sceptics, I'm sorry for you. I'm sorry you can't dream big and I'm sorry you don't believe in miracles.”

Lance Armstrong, 2005.

Acknowledgements

First and foremost I would like to thank my parents, Jenny and Phil, who encouraged me throughout my formative years to believe in myself and to take whichever opportunities arose, no matter how large or small. Their guidance and counsel gave me the confidence to accept this challenge offered by Professor Gordon Dougan (Doog).

To Doog, many thanks for introducing me to molecular microbiology, training me and above all, persisting with me, I hope I have upheld your belief.

Most importantly I would like to thank my best friend and wife, Kura who has stood by me for all these years, always believing. Kura has been a rock and inspiration to me since we met and has always offered unconditional support to all of my pursuits.

During my PhD, I have received substantial guidance from Dr Robert Kingsley (Dr Bob). He has honed my scientific skills over the four years I've been at the Sanger Institute, many thanks Dr Bob. I would also like to thank rest of Doog's team, those who have directly helped with experiments or those who have just put things away I forgetfully left around the lab.

Finally, many thanks to the Wellcome Trust who have underwritten this body of work.

Declaration	1
Abstract	2
Acknowledgements.....	4
Tables.....	10
Figures.....	11
Abbreviations	13
1 Introduction	15
1.1 The genus <i>Salmonella</i>	16
1.1.1 Classification and nomenclature	16
1.2 Disease syndromes caused by <i>Salmonella</i>	18
1.3 <i>Salmonella</i> pathogenicity	21
1.3.1 The biology of <i>Salmonella</i> infection.....	22
1.3.2 Typhoid vaccines.....	25
1.4 The genomics of invasive <i>Salmonella</i>	27
1.5 Genetics of <i>Salmonella</i> disease.....	33
1.5.1 TTSSs	33
1.5.2 The virulence (Vi) antigen.....	39
1.5.3 Horizontally acquired DNA.....	40
1.5.4 Adherence	41
1.5.5 Motility	42
1.5.6 Two-component regulators and virulence	42
1.6 Regulation of bacterial gene expression.....	44
1.6.1 Transcriptional activation	45
1.6.2 Post-transcriptional control.....	49
1.7 DNA sequencing technologies.....	49
1.7.1 DNA microarrays	49
1.7.2 High-capacity DNA sequencing	51
1.8 <i>In silico</i> - software and tools.....	52
1.8.1 Artemis and Artemis Comparison Tool (ACT)	53
1.8.2 BLAST and other packages	53
1.9 Aims of the Thesis	53
2 Materials and Methods.....	54
2.1 General chemicals, reagents and buffers.....	55
2.2 Bacterial strains.....	55
2.3 Plasmids.....	55
2.4 Microbiological media and techniques	56
2.4.1 Bacterial culture	56
2.4.1.1 Standard methods	56
2.4.1.2 Minimal media	58
2.4.2 Harvesting of bacteria from broth cultures.....	58
2.4.3 Growth curves.....	58
2.4.4 Identification of bacteria.....	59
2.5 Molecular biology techniques.....	59
2.5.1 Bacterial genomic DNA extraction.....	59
2.5.2 Plasmid DNA extraction.....	60
2.5.3 Agarose gel electrophoresis	60
2.5.4 Quantification of DNA and RNA by spectroscopy.....	61

2.5.5 DNA manipulation techniques.....	61
2.5.5.1 DNA restriction	61
2.5.5.2 Oligonucleotides.....	61
2.5.5.3 Polymerase chain reaction (PCR).....	64
2.5.5.3.1 PCR supermix (Invitrogen)	64
2.5.5.3.2 PFU polymerase high fidelity PCR.....	65
2.5.5.3.3 Real time PCR	65
2.5.5.3.4 Overlap extension PCR.....	66
2.5.5.4 Purification of PCR products	66
2.5.5.5 Cloning.....	66
2.5.5.5.1 Cloning PCR amplicons.....	66
2.5.5.5.2 Sub-cloning sequences into pWT12	67
2.5.6 Precipitation of DNA.....	67
2.5.7 DNA sequencing	67
2.5.7.1 Capillary-based sequencing	67
2.5.7.2 Illumina sequencing.....	68
2.5.8 DNA transformation.....	69
2.5.8.1 Transformation of chemically competent cells	69
2.5.8.1.1 Preparation of chemically competent cells.....	69
2.5.8.1.2 Chemical transformation.....	69
2.5.8.2 Transformation by electroporation	70
2.5.8.2.1 Preparation of electrocompetent cells.....	70
2.5.8.2.2 Electroporation	70
2.5.8.3 Screening for transformed DNA	71
2.5.8.3.1 Screening for non recombinant DNA	71
2.5.8.3.2 Screening for recombinant DNA	71
2.5.9 Bacterial conjugation.....	71
2.5.10 Transduction.....	72
2.5.10.1 Infection of donor strain with P22 phage.....	72
2.5.10.2 Isolation of P22 phage containing genomic DNA.....	72
2.5.10.3 Infection of recipient strain with P22 phage	72
2.5.11 Mutagenesis	73
2.5.11.1 Red recombinase mutagenesis.....	73
2.5.11.2 FLP recombinase mutagenesis	74
2.5.11.3 Allelic exchange mediated by suicide vector constructs	74
2.5.12 RNA methodologies	75
2.5.12.1 RNA stabilisation	75
2.5.12.2 RNA isolation.....	75
2.5.12.2.1 RNA isolation for microarray.....	75
2.5.12.2.2 RNA isolation for Illumina sequencing	76
2.5.12.2.3 rRNA removal	76
2.5.12.3 Removal of DNA from RNA samples.....	76
2.5.12.4 Reverse transcription of RNA	77
2.5.12.4.1 Reverse transcription of RNA for aminoallyl labelling.....	77
2.5.12.4.2 Reverse transcription of RNA for Illumina sequencing and real time PCR.....	77
2.5.12.5 Labelling of RNA for microarray.....	77
2.5.12.5.1 Purification of cDNA	77
2.5.12.5.2 Coupling of CyDye™ ester to dUTP.....	78
2.5.12.5.3 Purification of labelled cDNA.....	78

2.5.13 DNA microarray.....	79
2.5.13.1 Hybridisation and scanning.....	79
2.5.13.2 Gridding and feature extraction.....	79
2.5.14 Protein methodologies.....	80
2.5.14.1 Preparation of protein.....	80
2.5.14.1.1 Whole cell lysate.....	80
2.5.14.1.2 Cellular fractionation.....	80
2.5.14.1.2.1 Cell lysis.....	80
2.5.14.1.2.2 Precipitation of the soluble fraction.....	81
2.5.14.1.2.3 Separation of the membrane fractions.....	81
2.5.14.1.3 Heat shock.....	82
2.5.14.1.4 Preparation of proteins for mass spectroscopy analysis.....	82
2.5.14.2 One-dimensional SDS-PAGE gel electrophoresis of proteins.....	82
2.5.14.3 Protein visualisation.....	82
2.5.14.3.1 Coomassie blue protein stain.....	82
2.5.14.3.2 Western blot.....	83
2.5.14.4 Immunoprecipitation for chIP-seq.....	83
2.5.14.5 chIP-seq data mapping and analysis.....	83
2.6 Murine model of Salmonellosis.....	84
2.6.1 Competitive infections.....	84
2.7 LC-MS analysis.....	85
2.8 Bioinformatics tools.....	87
2.8.1 Artemis and ACT.....	87
2.8.2 Mapping software.....	89
2.8.2.1 Transcriptome mapping software.....	89
2.8.2.1 Protein mapping scripts.....	91
2.8.3 Perl scripts.....	91
2.8.3.1 Pileup to stranded plot - maqpileup2depth.pl.....	91
2.8.3.2 Local plots.....	91
2.8.3.3 Extracting expression data from plot.....	91
2.8.4 R.....	92
2.8.4.1 Limma analysis.....	92
2.8.5 Genespring.....	93
2.8.6 Graph pad prism 5.0.....	93
3 A Method for RNA-seq in prokaryotes.....	94
3.1 Aims of the work described in this Chapter.....	95
3.2 Introduction.....	95
3.3 Results.....	96
3.3.1 Directional Sequencing of Single Stranded cDNA.....	96
3.3.2 Sequencing of the <i>S. Typhi</i> transcriptome.....	100
3.3.3 Mapping and visualising data.....	103
3.4 Discussion and conclusion.....	105
4 Deep sequencing of the <i>S. Typhi</i> Ty2 transcriptome.....	107
4.1 Aims of the work described in this Chapter.....	108
4.2 Introduction.....	108
4.3 Results.....	109
4.3.1 Mapping Sequence Reads to the Annotated Ty2 Genome.....	109
4.3.2 Coding Sequences.....	112
4.3.2.1 General Features.....	112
4.3.2.2 Virulence Genes.....	118

4.3.2.3	Phage and putative cargo genes.....	121
4.3.2.4	Pseudogenes	122
4.3.2.5	Hypothetical Genes.....	123
4.3.2.6	A <i>S. Typhi</i> Ty2 Specific Insertion.....	123
4.3.3	Non-Coding Sequences	124
4.3.4	Transcriptome comparison with <i>ompR</i> -null mutant.....	129
4.3.4.1	Quality control.....	129
4.3.4.2	General features of the BRD948 <i>ompR</i> transcriptome	133
4.3.4.3	Quantified differences.....	134
4.3.4.4	Quantified differences pre-Benjamini Hochberg correction.....	137
4.4	Discussion.....	137
4.4.1	General transcriptome results.....	137
4.4.2	OmpR comparison.....	139
4.5	Conclusion.....	141
5	Global transcriptome analysis of an <i>S. Typhi ompR</i> -null Mutant.	142
5.1	Aims of this chapter	143
5.2	Introduction.....	143
5.3	Results	145
5.3.1	Analysis of the <i>S. Typhi</i> OmpR regulon, preliminary work.....	145
5.3.2	Microarray analysis	145
5.3.2.1	Biological conditions, quality control and analysis.....	145
5.3.2.2	The OmpR regulon during exponential growth (OD ₆₀₀ =0.6)	148
5.3.2.3	The OmpR regulon during early stationary phase (OD ₆₀₀ =1.1).....	150
5.3.2.4	The OmpR regulon grown under SPI-2 inducing conditions.....	151
5.3.3	Real time PCR confirmation of expression profile	152
5.3.4	Succinate dehydrogenase enzyme assay	153
5.3.5	chIP-seq to determine ompR-binding domains.....	155
5.3.5.1	Rabbit anti-OmpR.....	155
5.3.5.2	Construction of an OmpR:3xFLAG	155
5.3.5.3	chIP-Seq Quality Control.....	156
5.3.5.4	chIP-Seq using the Illumina sequencing platform.....	157
5.3.5.6	Comparison with genes differentially transcribed in microarray data	159
5.4	Discussion.....	160
5.4.1	Microarray Data	160
5.4.1.1	Regulators	161
5.4.1.2	Membrane transport.....	163
5.4.1.3	Respiration	165
5.4.1.4	Chemotaxis and motility	167
5.4.1.5	Genes of unknown function	167
5.4.1.6	Indirect comparison with RNA-seq data.....	168
5.4.2	chIP-seq	170
5.5	Conclusion	171
6	Characterisation of Hypothetical Genes in the OmpR Regulon.....	172
6.1	Aims of this chapter	173
6.2	Introduction.....	173
6.3	Results	174
6.3.1	<i>In silico</i> analyses	174
6.3.1.1	t1787-t1793 exhibited increased expression in the <i>ompR</i> mutant	175
6.3.1.2	t4498-4501 exhibited decreased expression in the <i>ompR</i> mutant	177

6.3.2	Identification of proteins using LC-MS.....	178
6.3.3	Construction of recombinant <i>S. Typhimurium</i> mutants in which homologues of t1787-1790, t1791-1793 and t4498-4501 are deleted	180
6.3.4	<i>in vitro</i> Phenotyping of Mutants	182
6.3.4.1	LPS silver stained gel	182
6.4.4.2	Growth on different carbon sources	183
6.4.5	<i>in vivo</i> phenotyping	184
6.4.5.1	Competitive infection assays.....	184
6.5	Discussion.....	187
6.5.1	RAK103 and RAK105 characterisation	187
6.5.2	TT56.1 phenotype	190
6.6	Conclusion.....	190
7	General Discussion	192
8	References	196
9	Appendices	216
9.1	Maqdeh2pileup.pl	216
9.2	extractLines.pl.....	218
9.3	tram.pl.....	220
9.4	LIMMA Analysis for Illumina data	221
9.5	Hypothetical gene sequence coverage.....	227
9.6	Non-coding RNA details	281
9.7	Differential expression pre-Benjamini-Hochberg correction	288
9.8	Microarray Differences	297
9.9	chIP data	302

Tables

Table 1.1 Salmonella nomenclature in use at CDC, 2000 [4].....	17
Table 1.2 Three years cumulative risk of typhoid fever (RR, 95% CI) [66]	27
Table 1.3 Genes unique to pairs of genomes [82]	31
Table 1.4. Effectors of the SPI1- and SPI2-encoded type III secretion systems [108]	36
Table 1.5 Major families of bacterial transcription factors [164]	46
Table 2.1 Strains used in this study	55
Table 2.2 Plasmids used in this study	56
Table 2.3 Antibiotic concentration and solvents	58
Table 2.4 Primers used in this study	62
Table 3.1 Read mapping for different depletion methods	102
Table 4.1 Analysis of sequences mapped to the Ty2 genome	110
Table 4.2. Sequence data mapped for each experiment	130
Table 4.3 Statistically different genes in the <i>ompR</i> mutant	135
Table 5.1 Genes differentially expressed in microarray experiments and with chIP-seq enrichment sites mapped upstream	159
Table 5.2 Experimentally verified and published genes in the OmpR regulon of <i>S.</i> <i>Typhi</i> or <i>S. Typhimurium</i> identified as being differentially regulated in the microarray experiments (2-fold, $p < 0.05$)	161
Table 6.1 Differentially expressed hypothetical genes and the published annotation	174
Table 6.2 Differentially expressed hypothetical genes re-annotated according to functional identity derived using pBLAST and Pfam database searches.....	178
Table 6.3 Growth on specific sole carbon sources	184

Figures

Figure 1.1 Disease syndromes and subspecies [7].	19
Figure 1.2 WHO estimates of the global burden of typhoid fever and its geographical distribution [8].	20
Figure 1.3 The horizontal transfer of virulence-associated genes within the genus <i>Salmonella</i> [78].	29
Figure 1.4 Analysis of the P4-like bacteriophage ST46 [89].	32
Figure 1.5 Model for substrate recognition and delivery of proteins by TTSS machines [96].	34
Figure 1.6 Cellular phenotypes associated with the function of SPI-2 [113].	38
Figure 1.7 Genetic structure of the <i>viaB</i> locus in <i>S. Typhi</i> Ty2.	40
Figure 1.8 Genetic content of horizontally acquired regions in <i>S. Typhi</i> CT18.	41
Figure 1.9 Some of the different combinations of histidine protein kinase (HPK) and aspartate response regulator (RR) domains in histidine–aspartate phosphorelay (HAP) systems [166].	48
Figure 1.10 Schematic of Illumina sequencing technology (http://www.illumina.com/).	52
Figure 3.1 The hypotheses proposed to account for the attachment of Illumina adapted dimers to <i>sscDNA</i> .	98
Figure 3.2 Single stranded sequencing.	99
Figure 3.3 Quantitative comparison of terminator exonuclease and oligonucleotide hybridisation rRNA depletion techniques.	103
Figure 3.4 Representation of transcriptomic sequence read coverage plot relative to genome annotation, as displayed in Artemis.	105
Figure 4.1 Circular plot of mapped sequence data.	111
Figure 4.2 Artemis representation of transcriptome plot.	112
Figure 4.3 Defined deletions in BRD948.	112
Figure 4.4 Sense and Antisense outliers.	114
Figure 4.5. Transcripts mapping to well characterised regions.	115
Figure 4.6 Consistency between sequencing experiments.	115
Figure 4.7 “Mosaic coding”.	116
Figure 4.8. Putative error in the annotation.	116
Figure 4.9. Functional classification of sequenced transcripts.	117
Figure 4.10. Attenuation.	118
Figure 4.11 Coverage for SPI-1.	119
Figure 4.12 Coverage across SPI-2.	120
Figure 4.13. Sequenced transcripts identifying cargo genes within <i>Salmonella</i> prophage.	122
Figure 4.14. Third Party Annotation of the Ty2-specific Insertion.	124
Figure 4.15 Coverage of putative non-coding RNAs.	126
Figure 4.16. SPI-1 Sequence coverage.	128
Figure 4.17. Paralogues of RUF107c.	129
Figure 4.18 Quality control.	132
Figure 4.19 Assigning transcriptome to functional class.	133
Figure 4.20. Start of the <i>viaB</i> locus.	134
Figure 4.21 Outer membrane porin C.	134
Figure 5.1 Quality control for expression microarrays.	147

Figure 5.2 Numbers of genes differentially transcribed by functional class.....	149
Figure 5.3 Circular plot of the <i>S. Typhi</i> genome and genes differentially transcribed in the <i>ompR</i> mutant.	150
Figure 5.4 Comparison of expression values determined by real-time PCR and microarray.....	153
Figure 5.5 Succinate dehydrogenase assay.	154
Figure 5.6 Schematic of overlap extension PCR to incorporate 3XFLAG peptide into the C-terminal region of OmpR.....	156
Figure 5.7 Western blot of immunoprecipitated OmpR:3XFLAG.....	157
Figure 5.8 Transporter transcript changes.....	164
Figure 5.9 Respiration.....	166
Figure 5.10 Genes of unknown function.....	168
Figure 5.11 Expression ratio for genes found to be differentially expressed in microarray and deep-sequencing experiments.....	169
Figure 6.1. Comparative alignment of regions predicted to be OmpR regulated in <i>S. Typhi</i>	176
Figure 6.2 The chemical structure of related acetylated aminosugars.....	177
Figure 6.3 Sequenced peptides mapped to regions predicted to be OmpR-regulated.	180
Figure 6.4 Details of mutagenesis for further phenotypic characterisation.	182
Figure 6.5 LPS silver stained gel.....	183
Figure 6.6 Control competitive infections.	186
Figure 6.7 Comparison of mutants RAK103 and TT56.1 with RAK113 (SL1344 Δ <i>phoN</i>).....	186

Abbreviations

Acronym	Definition
ACT	Artemis comparison tool
ADS	arginine deiminase
AM	arithmetic mean per base-pair
ATP	adenosine tri-phosphate
BLAST	basic local alignment search tool
bp	base-pair
CDC	Centre for Disease Control
cDNA	complementary DNA
CDS	coding sequence
CFU	colony forming units
CGH	comparative genome hybridisation
chIP	chromatin immunoprecipitation
CL3	containment level 3
DEPC	diethylpyrocarbonate
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
DTT	dithiothreitol
<i>E. coli</i>	<i>Escherichia coli</i>
EDTA	ethylenediaminetetraacetic acid
EGTA	ethylene glycol tetraacetic acid
FDR	false discovery rate
FNR	false non-discovery rate
gDNA	genomic DNA
HAP	histidine aspartate phosphorelay
HIV	human immunodeficiency virus
HPK	histidine protein kinase
JCICSB	Judicial Commission of the International Committee of Systematic Bacteriology
LASER	light amplification by stimulated emission of radiation
LB	Luria-Bertani
LC-MS	liquid chromatography mass spectroscopy
LPS	lipopolysaccharide
M cells	Microfold cells
MOPS	3-(N-morpholino)propanesulfonic acid
mRNA	messenger RNA
NAG	N-acetyl glucosamine
NAM	N-acetylmuramic acid
NB	Note
nc	nucleotide
NCBI	National Center for Biotechnology Information
ncRNA	non-coding RNA
Nramp-1	natural resistance-associated macrophage protein one
NTS	Non-typoidal Salmonella
ORF	open reading frame
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline

PCR	polymerase chain reaction
PMN	polymorphonuclear
RES	reticuloendothelial system
RNA	ribonucleic acid
RR	response regulator
rRNA	ribosomal RNA
RUF	RNA of unknown function
S.	<i>Salmonella enterica</i> serovar <i>enterica</i>
SCV	<i>Salmonella</i> containing vacuole
SDS	sodium dodecyl sulfate
SPI	<i>Salmonella</i> Pathogenicity Island
STM	signature tagged mutagenesis
TCA	trichloroacetic acid
tRNA	transfer RNA
TTSS	type three secretion system
UDP	uridine diphosphate
USA	United States of America
UTR	untranslated region
UV	ultraviolet
WHO	World Health Organisation
WT	wild-type
WTSI	Wellcome Trust Sanger Institute